William Blair Investment Management LLC Has $168.01 Million Stake in Insmed Incorporated (NASDAQ:INSM)

William Blair Investment Management LLC lifted its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 0.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,433,443 shares of the biopharmaceutical company's stock after purchasing an additional 12,535 shares during the quarter. William Blair Investment Management LLC owned 1.36% of Insmed worth $168,005,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC boosted its stake in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management acquired a new position in Insmed during the fourth quarter worth $47,000. Smartleaf Asset Management LLC raised its position in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in Insmed during the fourth quarter worth $86,000.

Insider Buying and Selling

In other news, CEO William Lewis sold 2,978 shares of the business's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the transaction, the chief executive officer now directly owns 392,589 shares of the company's stock, valued at $24,874,439.04. The trade was a 0.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Martina M.D. Flammer sold 6,172 shares of the firm's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the sale, the insider now directly owns 101,549 shares of the company's stock, valued at $6,462,578.36. This represents a 5.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 550,957 shares of company stock valued at $42,992,528 over the last quarter. Insiders own 4.60% of the company's stock.

Remove Ads

Analysts Set New Price Targets

INSM has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating and set a $90.00 target price on shares of Insmed in a research note on Friday, February 21st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 target price on shares of Insmed in a research report on Wednesday. Truist Financial lifted their price target on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Bank of America upped their price objective on Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a report on Thursday. Finally, UBS Group boosted their target price on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $94.00.

Insmed Trading Up 1.5 %

NASDAQ INSM traded up $1.15 on Friday, reaching $79.92. The company had a trading volume of 1,928,336 shares, compared to its average volume of 2,173,512. The firm has a market cap of $14.47 billion, a price-to-earnings ratio of -14.30 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The business has a 50 day moving average of $77.14 and a two-hundred day moving average of $73.77.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.